Ashland Inc reported 7% year-over-year sales growth in Q3 2026, driven by volume increases in Life Sciences and Personal Care. However, profitability declined due to production challenges and cost pre
Ashland Global Holdings reported strong Q3 2026 results, beating expectations with $1.02 EPS and $497 million revenue. Growth was driven by robust demand in its Life Sciences segment, specifically pha
Ashland Global Holdings reported Q3 fiscal 2026 adjusted earnings of $1.02 per share, missing estimates, while sales rose 7% to $497 million driven by volume growth. The company maintained sales guida
Ashland Inc. reported Q3 adjusted EPS of $1.02, exceeding FactSet estimates of $0.98. This indicates stronger than anticipated financial performance for the quarter.
Ashland Global Holdings reported Q3 results in line with expectations and reaffirmed full-year guidance. Strong performance in Life Sciences and Personal Care segments supported the outlook despite lo
Ashland Inc. reported Q3 revenue of $497.0 million, exceeding FactSet estimates of $486.0 million. Additionally, the company reaffirmed its 2026 revenue outlook between $1.84 billion and $1.87 billion
ChemBrief